Xiaowen Sun

机构：Pfizer (United States) · ORCID：0000-0002-5195-1231

发表论文 55 篇 · 总被引 891 次 · h-index 15

代表论文

• LXA4 enhances prostate cancer progression by facilitating M2 macrophage polarization via inhibition of METTL3 (2022 · International Immunopharmacology · 被引 30)
• Analysis of factors impacting postoperative pain and quality of life in patients with mixed hemorrhoids: A retrospective study (2024 · World Journal of Gastrointestinal Surgery · 被引 19)
• Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial (2025 · The Lancet Oncology · 被引 17)
• A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer (2017 · Cancer Chemotherapy and Pharmacology · 被引 12)
• A new imaging platform ( iScreen ) allows for the concurrent assessment of micronucleus induction and genotoxic mode of action in human A375 cells (2022 · Environmental and Molecular Mutagenesis · 被引 9)
• Conversion Surgery After Trastuzumab-Based Chemotherapy and Immunotherapy for Stage IV HER2-Positive Gastric Cancer: A Retrospective Multicenter Cohort Study (2025 · Annals of Surgical Oncology · 被引 5)